Scott Wilkinson

Scott T. Wilkinson is a clinical researcher focused on the psychopharmacology and therapeutic application of rapid-acting antidepressants, especially ketamine and esketamine, in mood and anxiety disorders. His work, as represented in multiple clinical studies and trials, examines both the acute psychoactive and dissociative effects of intravenous ketamine as well as strategies to sustain its antidepressant benefit, including combining ketamine with cognitive behavioural therapy. He has also contributed to comparative effectiveness research (ketamine versus electroconvulsive therapy) and to long-term safety and efficacy evaluations of esketamine in treatment-resistant depression.

Wilkinson's contributions span symptomatic characterisation, trial methodology and translational implications for clinical practice: quantifying acute clinician-observed dissociative states during ketamine administration, testing adjunctive psychotherapeutic approaches to prolong antidepressant response, and analysing extension-phase data on repeated esketamine dosing and its safety profile. His research informs clinical decision-making around integrating rapid-acting NMDA-receptor modulating treatments into care pathways for people with refractory depressive illness and suicidality risks.